drugset / Trial / NCT06141889

Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers

NCT06141889

Phase 1 Completed 16 enrolled BioAge Labs, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

This study is a single-dose, open-label, randomized crossover and multiple-dose, open-label study to evaluate the PK of azelaprag in older adult healthy volunteers.

Timeline

Start
2023-11-17
Primary completion
2024-01-26
Completion
2024-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Azelaprag Small molecule Oral

Indications

No indication recorded.